Edwards Lifesciences Corp (EW)

Vienna


	Symbol		Exchange		Currency
	EW		NYSE		USD	Real-time
	EW		Mexico		MXN	Delayed
	1EW		Milan		EUR	Real-time
	EW		TradeGate		EUR	Delayed
	EW		Frankfurt		EUR	Delayed
	E1WL34		B3		BRL	Delayed
	EW		Vienna		EUR	Real-time

Currency in EUR

Disclaimer

62.97

+0.67(+1.08%)

Closed11/10

Fair Value

Day's Range

62.04

62.97

52 wk Range

54.50

88.28

EW Income Statement

Featured here, the Income Statement (earnings report) for Edwards Lifesciences Corp, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

4,348

4,386.3

5,232.5

5,382.4

6,004.8

Total Revenues Growth

+16.79%

+0.88%

+19.29%

+2.86%

+11.56%

Cost Of Revenues

1,114.4

1,080.6

1,248.9

1,078.8

1,379.8

Gross Profit

3,233.6

3,305.7

3,983.6

4,303.6

4,625

Gross Profit Growth

+16.17%

+2.23%

+20.51%

+8.03%

+7.47%

Gross Profit Margin %

74.37%

75.36%

76.13%

79.96%

77.02%

Other Operating Expenses, Total

1,995.1

1,989.5

2,397.1

2,511.7

2,895.2

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+16.63%	-0.28%	+20.49%	+4.78%	+15.27%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	752.7	760.7	903.1	945.2	1,071.8
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,242.4	1,228.8	1,494	1,566.5	1,823.4
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

1,238.5

1,316.2

1,586.5

1,791.9

1,729.8

Operating Income Growth

+15.45%

+6.27%

+20.54%

+12.95%

-3.47%

EBIT Margin %

28.48%

30.01%

30.32%

33.29%

28.81%

Net Interest Expenses

11.5

7.6

-1

16.3

49.6

Net Interest Expenses Growth

+447.62%

-33.91%

-113.16%

+1,730%

+204.29%

Interest Expense, Total

-20.7

-15.8

-18.4

-19.2

-17.6

Interest And Investment Income

32.2

23.4

17.4

35.5

67.2

Other Non Operating Expenses, Total

8.8

12.2

15.8

17.6

22

EBT, Excl. Unusual Items

1,258.8

1,336

1,601.3

1,825.8

1,801.4

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-91.9

-419

103.5

23.8

-194.5

EBT, Incl. Unusual Items

1,166.5

916.7

1,702

1,767.4

1,598.1

EBT, Incl. Unusual Items Growth

+53.2%

-21.41%

+85.67%

+3.84%

-9.58%

EBT, Incl. Unusual Items Margin

26.83%

20.9%

32.53%

32.84%

26.61%

Income Tax Expense

119.6

93.3

198.9

245.5

198.7

Net Income to Company

1,046.9

823.4

1,503.1

1,521.9

1,399.4

Minority Interest

-

-

-

-

3

Net Income

1,046.9

823.4

1,503.1

1,521.9

1,402.4

Net Income Growth

+44.96%

-21.35%

+82.55%

+1.25%

-7.85%

Net Income Margin %

24.08%

18.77%

28.73%

28.28%

23.35%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

1,046.9

823.4

1,503.1

1,521.9

1,402.4

Basic EPS - Continuing Operations

1.68

1.32

2.41

2.46

2.31

Basic EPS - Continuing Operations Growth

+45.61%

-21.07%

+82.34%

+1.95%

-5.98%

Diluted EPS - Continuing Operations

1.64

1.3

2.38

2.44

2.3

Diluted EPS - Continuing Operations Growth

+45.13%

-20.73%

+83.08%

+2.52%

-5.74%

Basic Weighted Average Shares Outstanding

624.8

622.6

623.3

619

606.7

Diluted Weighted Average Shares Outstanding

636.7

631.9

631.2

624.2

609.4

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

1,327.8

1,423.4

1,721.3

1,931.5

1,874.7

EBITDA Growth

+15.44%

+7.2%

+20.93%

+12.21%

-2.94%

EBITDA Margin %

30.54%

32.45%

32.9%

35.89%

31.22%

EBIT